Table 1.
Patient characteristics.
| Variables | Total | PD-L1 (−) | PD-L1 (+) | P value |
|---|---|---|---|---|
| 54 (80.6%) | 13 (19.4%) | |||
| Age (Median) | 48 | 51 (38–73) | 45 (22–72) | |
| Sex | 0.82 | |||
| Male | 38 | 31 (81.6%) | 7 (18.4%) | |
| Female | 29 | 23 (79.3%) | 6 (20.7%) | |
| ECOG | 0.99 | |||
| 0 | 3 | 3 (100%) | 0 (0.0%) | |
| 1 | 36 | 28 (77.8%) | 8 (22.2%) | |
| 2 | 26 | 21 (80.8%) | 5 (19.2%) | |
| Not available | 2 | 2 (100%) | 0 (0.0%) | |
| Histologic variant | 0.22 | |||
| Leiomyosarcoma | 18 | 15 (83.3%) | 3 (16.7%) | |
| Undifferentiated pleomorphic sarcoma | 13 | 9 (69.2%) | 4 (30.8%) | |
| Angiosarcoma | 8 | 5 (62.5%) | 3 (37.5%) | |
| Synovial sarcoma | 6 | 6 (100%) | 0 (0.0%) | |
| Myofibroblastic sarcoma | 6 | 5 (83.3%) | 1 (16.7%) | |
| MPNST | 5 | 3 (60%) | 2 (40%) | |
| Etc* | 11 | 11 (100%) | 0 (0.0%) | |
| Primary site | 0.23 | |||
| Abdomen/pelvis | 23 | 20 (87.0%) | 3 (13.0%) | |
| Extremity | 22 | 19 (86.4%) | 3 (13.6%) | |
| Thorax | 18 | 13 (72.2%) | 5 (27.8%) | |
| Head/neck | 4 | 2 (50%) | 2 (50%) | |
| FNCLCC grade | 0.36 | |||
| I | 6 | 6 (100%) | 0 (0.0%) | |
| II | 33 | 27 (81.8%) | 6 (19.2%) | |
| III | 28 | 21 (75%) | 7 (25%) | |
| Number of previous chemotherapy | 0.83 | |||
| 1 | 48 | 38 (79.2%) | 10 (20.8%) | |
| 2 | 18 | 15 (83.3%) | 3 (16.7%) | |
| 3 | 1 | 1 (100%) | 0 (0.0%) | |
| Type of previous chemotherapy received | NA | |||
| Doxorubicin monotherapy | 9 | 7 (77.8%) | 2 (22.2%) | |
| Ifosfamide monotherapy | 3 | 2 (66.7%) | 1 (33.3%) | |
| Paclitaxel | 4 | 3 (75.0%) | 1 (25.0%) | |
| Doxorubicin combination | 33 | 28 (84.8%) | 5 (15.2%) | |
| Ifosfamide combination | 4 | 3 (66.7%) | 1 (33.3%) | |
| Cyclophosphamide based | 14 | 11 (78.6%) | 3 (21.4%) | |
| Gemcitabine/docetaxel | 14 | 12 (85.7%) | 2 (14.3%) | |
* 8th edition of the American Joint Committee on Cancer guideline of tumor, node, and metastasis (TNM) classification
*Etc: ASPS (alveolar soft part sarcoma, n = 3), epithelioid sarcoma (n = 3), DSRCT (desmoplastic small round cell tumors, n = 1), osteosarcoma (n = 1), liposarcoma (n = 1), rhabdomyosarcoma (n = 1), and PECOMA (perivascular epithelioid cell tumors, n = 1)
Abbreviation: Eastern Cooperative Oncology Group (ECOG), malignant peripheral nerve sheath tumor (MPNST), Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC)